Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050006/S119

GORE CARDIOFORM Septal Occluder; GORE CARDIOFORM ASD Occluder

W. L. Gore & Associates, Inc. · Decision date Aug 3, 2026

FDA DECISIONP050006/S119

What did the FDA approve?

FDA records P050006/S119 as a supplement to PMA P050006, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Aug 3, 2026.

FDA approval order statement

Approval for modifications to the Instructions for Use (IFU) for the GORE CARDIOFORM Septal Occluder and GORE CARDIOFORM ASD Occluder to add instructions of optional delivery system manipulation techniques in the event of a delayed lock has occurred at device deployment
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Aug 3, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P050006/S119
Regulatory pathway
PMA supplement
Product code
MLV
Decision code
APPR
Decision date
Aug 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transcatheter septal occluder.

Product code
MLV
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P050006/S116 · Related supplement

    GORE CARDIOFORM Septal Occluder; GORE CARDIOFORM ASD Occluder

  2. P050006/S117 · Related supplement

    GORE CARDIOFORM ASD Occluder; GORE CARDIOFORM Septal Occluder

  3. P050006/S118 · Related supplement

    GORE CARDIOFORM Septal Occluder

  4. P050006/S119 received

    Application receipt date recorded by FDA.

  5. P050006/S119 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P050006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050006

Product / regulatory recordCompanyPathwayDecision dateSource
W. L. Gore & Associates, Inc.PMA supplementDec 19, 2025FDA
W. L. Gore & Associates, Inc.PMA supplementFeb 20, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementMay 8, 2026FDA

Explore the linked device profile

Other records with product code MLV

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
32360 N. N. Valley Pkwy., Phonix, AZ, 85085

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records